Cytogen Statistics
Total Valuation
Cytogen has a market cap or net worth of KRW 77.05 billion. The enterprise value is 51.02 billion.
Market Cap | 77.05B |
Enterprise Value | 51.02B |
Important Dates
The next estimated earnings date is Thursday, May 15, 2025.
Earnings Date | May 15, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Cytogen has 23.07 million shares outstanding. The number of shares has increased by 23.54% in one year.
Current Share Class | 23.07M |
Shares Outstanding | 23.07M |
Shares Change (YoY) | +23.54% |
Shares Change (QoQ) | +1.78% |
Owned by Insiders (%) | 18.32% |
Owned by Institutions (%) | 0.03% |
Float | 11.72M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 7.06 |
PB Ratio | 1.57 |
P/TBV Ratio | 2.19 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -2.98 |
EV / Sales | 4.68 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -4.84 |
Financial Position
The company has a current ratio of 10.20, with a Debt / Equity ratio of 0.30.
Current Ratio | 10.20 |
Quick Ratio | 9.71 |
Debt / Equity | 0.30 |
Debt / EBITDA | n/a |
Debt / FCF | -1.41 |
Interest Coverage | -5.10 |
Financial Efficiency
Return on equity (ROE) is -33.46% and return on invested capital (ROIC) is -9.89%.
Return on Equity (ROE) | -33.46% |
Return on Assets (ROA) | -9.07% |
Return on Invested Capital (ROIC) | -9.89% |
Return on Capital Employed (ROCE) | -15.74% |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | 0.15 |
Inventory Turnover | 9.25 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -68.98% in the last 52 weeks. The beta is -0.10, so Cytogen's price volatility has been lower than the market average.
Beta (5Y) | -0.10 |
52-Week Price Change | -68.98% |
50-Day Moving Average | 3,935.60 |
200-Day Moving Average | 5,893.28 |
Relative Strength Index (RSI) | 36.61 |
Average Volume (20 Days) | 85,656 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Cytogen had revenue of KRW 10.91 billion and -17.12 billion in losses. Loss per share was -758.00.
Revenue | 10.91B |
Gross Profit | 2.83B |
Operating Income | -10.67B |
Pretax Income | -17.93B |
Net Income | -17.12B |
EBITDA | -8.58B |
EBIT | -10.67B |
Loss Per Share | -758.00 |
Balance Sheet
The company has 41.27 billion in cash and 14.87 billion in debt, giving a net cash position of 26.39 billion or 1,144.13 per share.
Cash & Cash Equivalents | 41.27B |
Total Debt | 14.87B |
Net Cash | 26.39B |
Net Cash Per Share | 1,144.13 |
Equity (Book Value) | 48.94B |
Book Value Per Share | 2,105.94 |
Working Capital | 43.36B |
Cash Flow
In the last 12 months, operating cash flow was -9.53 billion and capital expenditures -1.01 billion, giving a free cash flow of -10.54 billion.
Operating Cash Flow | -9.53B |
Capital Expenditures | -1.01B |
Free Cash Flow | -10.54B |
FCF Per Share | -456.70 |
Margins
Gross margin is 25.93%, with operating and profit margins of -97.75% and -156.88%.
Gross Margin | 25.93% |
Operating Margin | -97.75% |
Pretax Margin | -164.35% |
Profit Margin | -156.88% |
EBITDA Margin | -78.61% |
EBIT Margin | -97.75% |
FCF Margin | n/a |
Dividends & Yields
Cytogen does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -23.54% |
Shareholder Yield | -23.54% |
Earnings Yield | -22.21% |
FCF Yield | -13.67% |
Stock Splits
The last stock split was on September 28, 2022. It was a forward split with a ratio of 3.
Last Split Date | Sep 28, 2022 |
Split Type | Forward |
Split Ratio | 3 |
Scores
Cytogen has an Altman Z-Score of 4.28.
Altman Z-Score | 4.28 |
Piotroski F-Score | n/a |